A Retrospective Evaluation of Eribulin Dosing Schedules in Metastatic Breast Cancer
Class of 2016 Abstract === Objectives: To determine the number of patients treated with eribulin who required an alternate dosing schedule other than “day 1/day 8” due to side effects. Methods: Chart reviews were conducted on all patients who met inclusion criteria. Data collected included patient...
| Main Authors: | , , |
|---|---|
| Language: | en_US |
| Published: |
The University of Arizona.
2016
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10150/613986 http://arizona.openrepository.com/arizona/handle/10150/613986 |
| Summary: | Class of 2016 Abstract === Objectives: To determine the number of patients treated with eribulin who required an alternate dosing schedule other than “day 1/day 8” due to side effects.
Methods: Chart reviews were conducted on all patients who met inclusion criteria. Data collected included patient demographics, history of surgery/radiation, number of past chemotherapy treatments, and lab values prior to each eribulin cycle.
Results: A total of 37 patients met inclusion criteria for this study. Ten patients were initially started on the “day 1/day 8” schedule and 3 of those patients required a change to the extended “day 1/day 15” schedule. The remaining 27 patients were started on the extended schedule.
Conclusions: The number of patients requiring a dosing schedule change due to side effects was not statistically significant. This finding was due to the fact that the majority of patients were started on an alternate dosing schedule in the beginning of treatment. More extensive studies would be required to determine if a majority of patients would require this alternate dosing schedule, and if this should be initiated in all patients starting on eribulin. |
|---|